Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy
CN Baxevanis, PA Sotiropoulou, NN Sotiriadou… - Cancer Immunology …, 2004 - Springer
Abstract HER-2/neu (also known as HER2 or c-erb-B2) is a 185-kDa protein receptor with
tyrosine kinase activity and extensive homology to the epidermal growth factor (EGF) …
tyrosine kinase activity and extensive homology to the epidermal growth factor (EGF) …
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
K Cathcart, J Pinilla-Ibarz, T Korontsvit, J Schwartz… - Blood, 2004 - ashpublications.org
A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease
C Yoshida, JV Melo - International journal of hematology, 2004 - Springer
Chronic myeloid leukemia (CML) is a stem cell disorder caused by a constitutively activated
tyrosine kinase, the Bcr-Abl oncoprotein. An inhibitor of this tyrosine kinase, imatinib …
tyrosine kinase, the Bcr-Abl oncoprotein. An inhibitor of this tyrosine kinase, imatinib …
Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)
S Mundhada, R Luthra, P Cano - BMC cancer, 2004 - Springer
Background Based on the site of breakpoint in t (9; 22)(q34; q11), bcr-abl fusion in leukemia
patients is associated with different types of transcript proteins. In this study we have seen …
patients is associated with different types of transcript proteins. In this study we have seen …
Proteosomal degradation of BCR/ABL protein can generate an HLA-A* 0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were …
EF Posthuma, CA Van Bergen, MG Kester… - …, 2004 - haematologica.org
BACKGROUND AND OBJECTIVES: Cytotoxic T-lymphocytes (CTL) have been generated in
vitro against chronic myeloid leukemia (CML)-associated BCR/ABL-specific peptides. We …
vitro against chronic myeloid leukemia (CML)-associated BCR/ABL-specific peptides. We …
Quantification of cell hybridoma yields with confocal microscopy and flow cytometry
M Gabrijel, U Repnik, M Kreft, S Grilc, M Jeras… - Biochemical and …, 2004 - Elsevier
The fusion of antigen presenting and cancer cells leads to the formation of hybrid cells,
which are considered a potential vaccine for treating cancer. The quality assessment of …
which are considered a potential vaccine for treating cancer. The quality assessment of …
[图书][B] Leukemia cell vaccine generation using lentiviral vectors
AC Logan - 2004 - search.proquest.com
Due to their ability to gain access to target cell genomes without mitosis-related dissolution
of the nuclear membrane, lentiviral vectors are useful tools for the genetic modification of …
of the nuclear membrane, lentiviral vectors are useful tools for the genetic modification of …
[引用][C] No proof of the existence of high-avidity T-cells capable of recognizing endogenously processed BCR/ABL-specific antigen presented in the context of HLA-A …
EFM Posthuma, CAM van Bergen, MGD Kester…